CANER, B. Et Al. 2022. Hyperprogression and hypercalcemia after nivolumab treatment in three cases with renal cell carcinoma. JOURNAL OF ONCOLOGY PHARMACY PRACTICE , vol.28, no.7 , 1645-1649.

CANER, B., Ertas, H., Ocak, B., & ÇUBUKÇU, E., (2022). Hyperprogression and hypercalcemia after nivolumab treatment in three cases with renal cell carcinoma. JOURNAL OF ONCOLOGY PHARMACY PRACTICE , vol.28, no.7, 1645-1649.

CANER, BURCU Et Al. "Hyperprogression and hypercalcemia after nivolumab treatment in three cases with renal cell carcinoma," JOURNAL OF ONCOLOGY PHARMACY PRACTICE , vol.28, no.7, 1645-1649, 2022

CANER, BURCU Et Al. "Hyperprogression and hypercalcemia after nivolumab treatment in three cases with renal cell carcinoma." JOURNAL OF ONCOLOGY PHARMACY PRACTICE , vol.28, no.7, pp.1645-1649, 2022

CANER, B. Et Al. (2022) . "Hyperprogression and hypercalcemia after nivolumab treatment in three cases with renal cell carcinoma." JOURNAL OF ONCOLOGY PHARMACY PRACTICE , vol.28, no.7, pp.1645-1649.

@article{article, author={BURCU CANER Et Al. }, title={Hyperprogression and hypercalcemia after nivolumab treatment in three cases with renal cell carcinoma}, journal={JOURNAL OF ONCOLOGY PHARMACY PRACTICE}, year=2022, pages={1645-1649} }